RecruitingNot ApplicableNCT04368663
The Beneficial Effect of TJ-134 for Patients With Symptomatic Pneumatosis Cystoides Intestinalis
The Beneficial Effect of the Traditional Japanese Medicine, Keishi-ka-shakuyaku-daio-to（TJ-134）for Patients With Symptomatic Pneumatosis Cystoides
Sponsor
Showa Inan General Hospital
Enrollment
100 participants
Start Date
May 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to is administered to patients with symptomatic pneumatosis cystoides intestinalis (PCI) as compared with lactomin for 8 weeks.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria1
- typical findings of PCI on colonoscopy; Line or pebble like sessile cysts are distributed around the colon with normal overlying mucosa
Exclusion Criteria1
- patients can not take Keishi-ka-shakuyaku-daio-to（TJ-134）
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGJapanese traditional medicine group
TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04368663